IsoPlexis

What IsoPlexis does

IsoPlexis is a life-science technology company that built a single-cell functional proteomics platform around its proprietary proteomic barcoding technology. Founded in 2013 and headquartered in Branford, Connecticut, the company developed benchtop instruments (IsoLight System, IsoSpark System) that capture highly multiplexed cytokine, chemokine, and phosphoprotein signatures from individual cells, paired with single-use chips (Single-Cell Secretome, Single-Cell Signaling, CodePlex: Walkaway Proteomics, Meteor: Quantitative Bulk Proteomics) and IsoSpeak software for data analysis and visualization. The technology is used to predict disease progression, treatment resistance, and therapeutic efficacy by linking functional proteomic readouts directly to single cells, with stated applications in therapeutic antibody discovery, cell and gene therapy, cancer immunology, and biomarker research.

The company sells high-value capital instruments, recurring consumables, and software licenses through direct enterprise field sales targeting pharmaceutical, biotechnology, and academic research customers. A Technology Access Program (TAP) provides an alternative, lower-friction entry point for labs to evaluate instruments without full capital purchase. Named customers and case-study users include Medical College of Wisconsin, Mycenax, and Abveris across academic and biotech segments. Cumulative disclosed private funding exceeded $200 million across rounds from 2014 to 2021, including an $85 million Series D led by Perceptive Advisors with Ally Bridge Group and BlackRock in January 2021.

IsoPlexis was acquired by Bruker and is now operated as part of Bruker Cellular Analysis, with the IsoLight, IsoSpark, and IsoSpeak lines marketed under the Proteomic Barcoding Suite. Post-acquisition, the product line is integrated with Bruker Spatial Biology's CosMx platform to combine live single-cell functional data with subcellular spatial imaging, and the Beacon optofluidic product family (Beacon Discovery, Beacon Quest, Beacon Select, Beacon Optofluidic System, Culture Station) has been brought into the same commercial organization. The company's original co-founder Rong Fan remains associated as a scientific advisor; current disclosed leadership includes John Strahley (CFO) and John Leamon (SVP R&D Integration).

Name

IsoPlexis

Website

https://isoplexis.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

101–250 employees

Short description

IsoPlexis, now part of Bruker Cellular Analysis, develops single-cell functional proteomics instruments (IsoLight, IsoSpark) and consumables (Single-Cell Secretome, Single-Cell Signaling, CodePlex, Meteor) plus IsoSpeak software for pharma, biotech, and academic research labs studying immune response, antibody discovery, and cell therapy.

Ownership category

akta.pro rank

Product category

Single-Cell Proteomics Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industries

Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Translational Medicine & Biomarkers (HLAIALAF), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Single-cell proteomics
• Proteomic barcoding instruments
• Multiplex cytokine profiling
• Single-cell functional analysis
• Immune response profiling

Headquarters

HQ city

Branford

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Instrument Sales: Sale of capital equipment including IsoLight and IsoSpark systems for single-cell proteomics analysis. These are high-value instruments sold to pharma, biotech, and academic research labs.
2. Consumables/Kits: Single-use chips and reagents including Single-Cell Secretome and Single-Cell Signaling chips that are consumed with each run.
3. Software Licenses: IsoSpeak software for data analysis, likely sold as subscriptions or licenses for ongoing access to updates and support.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

IsoPlexis (now part of Bruker Cellular Analysis) develops and sells the Proteomic Barcoding Suite, which includes the IsoLight and IsoSpark benchtop instruments that capture highly multiplexed cytokine, chemokine, and phosphoprotein signatures from single cells, paired with single-use chip consumables (Single-Cell Secretome, Single-Cell Signaling, CodePlex, Meteor) and the IsoSpeak data analysis software. The platform enables researchers in pharma, biotech, and academic labs to predict disease progression, treatment resistance, and therapeutic efficacy by linking functional readouts directly to individual cells.

Product overview

IsoPlexis, now part of Bruker Cellular Analysis, offers the Proteomic Barcoding Suite—a platform of instruments, chips, and software for single-cell and bulk proteomics analysis. The core instruments include the IsoLight System and IsoSpark System for capturing multiplexed cytokine, chemokine, and phosphoprotein signatures from single cells. These are complemented by chip products (Single-Cell Secretome, Single-Cell Signaling, CodePlex: Walkaway Proteomics, Meteor: Quantitative Bulk Proteomics) and the IsoSpeak Software for data analysis and visualization. The suite enables researchers to predict disease progression, treatment resistance, and therapeutic efficacy through comprehensive proteomics profiling.

Differentiator

Problem solved

Functional benefit

Brands

• IsoLight System: Single-cell proteomics system for proteomic barcoding workflow
• IsoSpark System
• IsoSpeak Software

Products and services

• IsoLight System

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• CosMx (Bruker Spatial Biology)coreTechnology or IntegrationIntegration between Beacon platforms and CosMx Spatial Molecular Imager enables linking live T cell function data with spatial biology insights. The combined solution provides single-cell functional data from Beacon instruments paired with subcellular resolution spatial imaging and true spatial context from CosMx on the same cells.

Recent moves6 records

Expansion highlights6 records

Direct peers

• 10x Genomics: 10x Genomics offers Chromium single-cell instruments and assays spanning genomics, transcriptomics, and multi-omics. It is the dominant incumbent in single-cell analysis and directly competes with IsoPlexis for cell therapy, immunology, and translational research workflows where researchers choose between platforms.
• Berkeley Lights (now PhenomeX): PhenomeX (formerly Berkeley Lights) sells optofluidic Beacon instruments for live single-cell functional screening in antibody discovery and cell line development. It is the most direct technology peer to IsoPlexis's optofluidic and functional proteomics offering and is explicitly highlighted on the Bruker Cellular Analysis website as adjacent technology.
• Standard BioTools (formerly Fluidigm): Standard BioTools manufactures the Hyperion imaging mass cytometry and CyTOF/Helios platforms for highly multiplexed single-cell protein profiling. It competes head-to-head with IsoPlexis on deep single-cell proteomic readouts for immunology and translational research customers.
• Mission Bio: Mission Bio's Tapestri platform performs single-cell multi-omics (DNA + protein) for clonal profiling in oncology and cell therapy. It targets overlapping translational and cell therapy customer segments where IsoPlexis sells its polyfunctional profiling workflows.
• Cytek Biosciences: Cytek sells Aurora and Northern Lights spectral flow cytometers used for high-parameter immune cell phenotyping. It competes with IsoPlexis for immunology and cell therapy customers seeking deep single-cell protein readouts, particularly where flow cytometry remains the workflow of choice.

Emerging players

• Parse Biosciences: Parse Biosciences offers scalable single-cell sequencing kits (Evercode) without dedicated instrumentation. While focused on transcriptomics rather than proteomics, it competes for single-cell project budgets in academic and translational labs that might otherwise purchase IsoPlexis instruments.
• Olink Holding (part of Thermo Fisher): Olink's proximity extension assay technology delivers highly multiplexed protein biomarker measurements from small samples. Recently acquired by Thermo Fisher, it competes for translational proteomics budgets and biomarker discovery projects that IsoPlexis targets in pharma and academic settings.

Broad incumbents

• BD Biosciences (Becton Dickinson): BD Biosciences offers the FACSDiscover S8 and BD CellView image-enabled cell sorters plus a broad flow cytometry portfolio. As a major life sciences incumbent with global reach, it is a default alternative for cell therapy and immunology customers evaluating IsoPlexis instruments.
• Bio-Techne: Bio-Techne provides a broad portfolio of life science reagents, proteins, and analytical tools including single-cell proteomics reagents (e.g., RNAscope, proteome profiler arrays). It is a broad incumbent that overlaps with IsoPlexis at the consumables and assay level rather than at the instrument level.
• NanoString Technologies: NanoString (now operating under Bruker ownership of its spatial biology assets) developed the CosMx and GeoMx spatial biology platforms that IsoPlexis integrates with via its CosMx partnership. It is adjacent rather than directly competitive and serves overlapping translational research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/isoplexis-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds11 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IsoPlexis